Company intelligence / Profile preview

Simcere Zaiming Pharmaceutical

Nanjing, Jiangsu, Chinasimcere.com ↗
Ownership
Private
Employees
~6815
Development stage
Other
01

Overview

Simcere Zaiming Pharmaceutical is an oncology-focused biopharmaceutical subsidiary of Simcere Pharmaceutical Group. The company has a diverse portfolio of approved innovative drugs in China, including Enzeshu (suvisexumab), COSELA (trilaciclib), and Enweida (envafolimab). Its clinical pipeline is characterized by multi-specific antibodies and ADCs, featuring high-value global partnerships with AbbVie, Ipsen, and NextCure. In early 2026, the company announced the successful dosing of patients in Phase 1 trials for advanced programs like its bispecific ADC SIM0610 and reported positive early results for its PD-L1/IL-15 fusion protein SIM0237.

Therapeutic areas
Oncology
Modalities
Monoclonal antibodyAntibody-drug conjugateSmall moleculeRecombinant proteinTrispecific antibodyBispecific antibodyBispecific antibody-drug conjugateRecombinant fusion protein
Industry
Biotech
02

Drug pipeline

2 assets

BCMA CAR NK cells

Unknown

1 more asset in the full pipeline.

03

Partnerships

AbbVieIpsenNextCurePyxis OncologyG1 Therapeutics3D MedicinesAlphamab OncologyTargetRx

Beyond the preview

Go deeper on Simcere Zaiming Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simcere Zaiming Pharmaceutical.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call